“…The O-demethylation mediated by CYP2D6 produces an active metabolite, bufotenine (Yu et al, 2003a). In addition, each study on the metabolism and disposition of 5-MeO-DMT was limited to a single dose (Agurell et al, 1969;Sitaram et al, 1987a,b;Barker et al, 2001;Shen et al, 2009Shen et al, , 2010b. Therefore, in this study we investigated 5-MeO-DMT pharmacokinetics in mice at multiple dose levels and through different routes of administration, which cover the range from nontoxic to toxic dose levels, aiming to define the pharmacokinetic properties of 5-MeO-DMT, delineate the impact of CYP2D6 on systemic clearance of 5-MeO-DMT, and develop a pharmacokinetic model to quantitatively characterize serum concentration-time profiles of 5-MeO-DMT.…”